Session » Antiphospholipid Syndrome: Basic Science

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

Abstract Number: 2174

Neutrophils in Primary Antiphospholipid Syndrome Are Characterized By a Prominent Activated Phenotype and Uniquely Remodeled Chromatin Architecture

Abstract Number: 2175

Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome

Abstract Number: 2176

The Ability of Recombinant Domain I of Beta-2-Glycoprotein I to Inhibit Lupus Anticoagulant Effect of IgG from Patients with APS Is Enhanced By Pegylation

Abstract Number: 2177

Pegylated Recombinant Domain I of Beta-2-Glycoprotein I, a Potential Therapeutic Agent for Antiphospholipid Syndrome, Fully Retains Its Ability to Inhibit Binding of IgG or IgA Antibodies from Patients with APS to Beta-2-Glycoprotein I in Vitro

Abstract Number: 2178

Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model

Abstract Number: 2179

Signaling By Mammalian Target of Rapamycin (mTORC) Highlight Pathological IgG and IgA in SLE Patients with Secondary APS

Abstract Number: 2180

Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors

Abstract Number: 2181

Antiphospholipid Antibody-Mediated Increase of Tissue Factor in Arterial Wall Is Associated with Increased Thrombus Size in a Mouse Model

« View all sessions from this meeting